Introduction
Neuroendovascular therapy is a less invasive method of treating various cerebrovascular diseases such as cerebral aneurysm, supra-aortic artery stenosis/ occlusion, arteriovenous shunts, and acute stroke [1] [2] [3] [4] [5] [6] [7] [8] that has become increasingly popular. however, the current status of this therapy including numbers of procedures, clinical outcomes, and adverse events remain unknown. 9, 10) The japanese Society of Neuroendovascular Therapy (jSNeT) established a board certification system in 2000 that certified physicians with ≥ 200 primary operator experiences, ≥ 10 presentations at medical meetings, and ≥ 3 publications as primary author as senior trainers and specialists through a board examination. The jSNeT produced an expert consensus document in 2009 when a systematic review revealed a scarcity of high-quality clinical evidence in this field, especially in japan. Thus, the society implemented retrospective studies (japanese registry of Neuroendovascular Therapy 1 and 2; jr-NeT1&2) to clarify the general status of neuroendovascular therapy delivered by jSNeT-certified physicians. clinical and procedural data were retrospectively collected from january 2005 through december 2007 (jr-NeT1) and from january 2008 through december 2009 (jr-NeT2).
These studies aimed to determine annual changes in neuroendovascular treatment modalities and in major adverse events within 30 days thereafter.
Methods

I. Study design JR-NET1 (2005-2006):
This was the first nationwide survey of neuroendovascular treatments in japan. The registry targeted all patients treated by jSNeT boardcertified physicians between january 2005 and december 2006, except for those whom their physicians judged unsuitable for this registry. medical information about the patients was anonymized and retrospectively registered via a website (https://jr-net.tri-kobe.net/jr-net/).
JR-NET2 (2007-2009):
This second nationwide survey of neuroendovascular treatment in japan targeted all patients treated by jSNeT board-certified physicians between january 2007 and december 2009. medical information of the patients was anonymized and registered as described above.
data were collected at the Translational research informatics center (Tri, http://www.tri-kobe.org/). The study protocol, which is summarized briefly here, is available on line with the full text of this article (https://jr-net.tri-kobe.net/jr-net/). all members of the writing committee assumed responsibility for the accuracy and completeness of the data and for the fidelity of the study with regard to the protocol.
II. Patients
all patients treated by neuroendovascular treatment at participating centers during the study period were basically enrolled in the study. The local institutional review boards at each institution approved the study protocol before the investigators proceeded with the study.
III. Primary and secondary endpoints
The primary endpoint was activities of daily life (adL) determined according to modified rankin scale (mrS) scores. The secondary endpoints comprised the technical success of procedures and major adverse events (maes) that occurred within and at 30 days after procedures. a score of 0 on the mrS indicates no disability, whereas scores of 1 or 2 indicate slight disability (some help required with adL but basically independent), scores of 3 to 5 indicate moderate disability (some help required with adL) to severe disability (bedridden or constant specific care required), and a score of 6 indicates death.
adverse events were classified as minor and major when mrS scores deteriorated by 1 and ≥ 2 points, respectively.
IV. Statistical analysis data were statistically analyzed using jmP 7 software (SaS institute, cary, North carolina, uSa). The statistical significance of intergroup differences was assessed using the t-test for quantitative scales, Pearson's χ 2 test; p < 0.05 was considered significant.
Results
I. Backgrounds and characteristics of patients
a total of 32,068 patients (mean age, 63.5 ± 13.9 mRS scores before and after treatment: Figure 4a and 4b shows the overall proportions of mrS scores before and after treatment. before treatment, ≥ 90% of patients were in relatively good condition, with mrS scores of 0-2 ( Fig. 4a) . at 30 days after undergoing procedures, > 80% of patients maintained mrS scores of 0-2 (Fig. 4b) . mRS scores after each type of procedure: Figure  5 shows the outcomes of each type of treatment years; female, 46.8%) were registered in this study (Table 1) , which involved 200 and 256 board-certified physicians at 122 and 150 centers in jr-NeT 11) and in jr-NeT2, respectively (appendix). Figure 1 shows the proportions of treated patients within various age groups. although patients aged between 40 years and 70 years were the main recipients of treatment, the rate of octogenarians increased annually from 7.0% in 2005 to 10.4% in 2009 (p < 0.001). in contrast, the ratio of younger patients (< 40 years) remained constant (p = 0.361; Fig. 1 ). Fig. 2) . Elective or emergency procedures: The total numbers of elective and emergency procedures increased annually, but the rate of emergency treatment remained relatively constant between 28% and 30% throughout the study period (Fig. 3) . Physicians in charge: Senior trainers certified by jSNeT were in charge of 63.6% and 48.9% of procedures complications. on the other hand, complications developed at a rate of 9.6% in patients treated for acute stroke, including 2.8% who died. Complication rates were higher after procedures for ruptured aneurysm (7.4%) and acute stroke (9.5%), but less frequent for those that treated unruptured aneurysms (2.8%), VA/SCA (1.5%), and tumor embolization (1.5%).
II. Procedures
according to mrS scores. outcomes were favorable for 61.7% and 96.3% of patients with ruptured and unruptured aneurysms, respectively, (mrS 0-2) and for ≥ 90% those after caS, Va/Sca, daVF, and tumors. on the other hand, 82.0%, 81.9%, and 37.2% of those treated for intracranial artery disease (icad), in aVm, and acute stroke had favorable outcomes. Procedural complications of each treatment: Figure  6 shows the frequency of procedural complications after each type of treatment. death, major and minor procedural complications occurred in 7.4% and 2.8% of patients treated for ruptured and unruptured aneurysms, respectively. among angioplasties, procedural complications occurred in 3.4%, 1.5%, and 5.4% in the carotid artery, the Va/Sca and in icad, respectively. among arteriovenous shunt diseases, complications developed in 5.2% and 3.0% of those treated for aVm and daVF, respectively. The rate of complications of tumor embolization was 1.5%, and none of the patients died of procedure-related (1,476 to 2,438), respectively. The mrS scores after procedures remained favorable in > 80% of the patients each year. clinical outcomes and complication rates significantly differed among procedures. rates of favorable outcomes of procedures to treat ruptured aneurysms and acute stroke were around 60% and < 40%, respectively, and more procedural complications were also associated with these conditions. however, whether complications were major or minor was sometimes difficult to judge in emergency patients under general anesthesia or sedation, and in patients with poor neurological status. Thus, procedural complications in these two groups might have been over-or underestimated.
Several reports have described nationwide trends in neuroendovascular therapies. [12] [13] [14] [15] [16] [17] [18] [19] Some of them are analyses of a national healthcare database in the united States. [12] [13] [14] [15] 17, 20) For example, huang et al. reported trends in the management of unruptured cerebral aneurysms in the united States. 15) They analyzed the length of hospital stay, in-hospital mortality rates, the number of hospitalizations, and total national charges related to inpatient treatment. Their findings provide valuable information regarding trends, but obtaining clinical data about neurological status, neuroendovascular procedures, and follow-up results might be difficult. detailed evaluations and analyses could be achieved if areas or centers were selected. higashida et al. described endovascular treatment for unruptured intracranial aneurysms in 18 of 47 states in the united Staes during 2007. 21 ) Qureshi et al. described how class i evidence (iSaT) from a nationwide impact survey impacted clinical practice. Their database was derived from stratified sampling at 20% of uS hospitals. 20) in that regard, data from the nationwide jr-NeT1&2 surveys are valuable because the study collected precise information regarding not only patient's characteristics, but also neurological status, types of treatment, devices, complications, and follow-up at 30 days after procedures.
This study has some limitations. although jr-NeT 1&2 provided a robust amount of patient information including clinical details, particularly information related to neuroendovascular therapies, it covered only about 35% of all procedures performed in japan, which was calculated according to annual reports of training facilities of the japan neurosurgical society (unpublished). This was a significant drawback in terms of avoiding selection bias. This shortcoming might be improved in a new nationwide survey (jr-NeT 3), which is collecting information between 2010 and 2013 in a similar setting to that of jr-NeT 1&2.
Conclusion
data from this study suggest an increasing trend towards neuroendovascular treatment in japan. The rate of neuroendovascular intervention is increasing annually and clinical outcomes seem acceptable. details about each treatment or disease will be assessed in sub-analyses of this database.
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